Indications and Route of Hysterectomy for Benign Diseases. 
Guideline of the DGGG, OEGGG and SGGG 
(S3 Level, AWMF Registry No. 015/070, April 2015)

Indikation und Methodik der Hysterektomie bei benignen Erkrankungen. 
Leitlinie der DGGG, OEGGG und SGGG (S3-Level, AWMF-Registernummer 015/070, April 2015)

Authors

Affiliations
The affiliations are listed at the end of the article.

Abstract

Background: Official guideline “indications and methods of hysterectomy” to assign indications for the different methods published and coordinated by the German Society of Gynecology and Obstetrics (DGGG), the Austrian Society of Gynecology and Obstetrics (OEGGG) and the Swiss Society of Gynecology and Obstetrics (SGGG). Besides vaginal and abdominal hysterectomy, three additional techniques have been implemented due to the introduction of laparoscopy. Organ-sparing alternatives were also integrated.

Methods: The guideline group consisted of 26 experts from Germany, Austria and Switzerland. Recommendations were developed using a structured consensus process and independent moderation. A systematic literature search and quality appraisal of benefits and harms of the therapeutic alternatives for symptomatic fibroids, dysfunctional bleeding and adenomyosis was done through MEDLINE up to 6/2014 focusing on systematic reviews and meta-analysis.

Results: All types of hysterectomy led in studies to high rates of patient satisfaction. If possible, vaginal instead of abdominal hysterectomy should preferably be done. If a vaginal hysterectomy is not feasible, the possibility of a laparoscopic hysterectomy should be considered. An abdominal hysterectomy should only be done with a special indication. Organ-sparing interventions also led to high patient satisfaction rates, but contain the risk of symptom recurrence.

Conclusion: As an aim, patients should be enabled to choose that therapeutic intervention for their benign disease of the uterus that convenes best to them and their personal life situation.

Zusammenfassung


Neis KJ et al. Indications and Route... Geburtsh Frauenheilk 2016; 76: 350–364
**Guideline Information**

Guidelines Program of the DGGG, OEGGG and SGGG. Information on this topic is provided at the end of the guideline.

**Citation format**

Indications and route of hysterectomy for benign diseases. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry No. 015/070, April 2015). Geburtsh Frauenheilk 2016; 76: 350–364

**Guideline documents**

The complete long version and a summary of the conflicts of interest of all of the authors in the Guideline methods report are available on the AWMF website:

http://www.awmf.org/leitlinien/detail/ll/015-070.html

**Authors**

See Table 1.

---

**Table 1** Authors.

<table>
<thead>
<tr>
<th>Author</th>
<th>DGGG working group/professional association/organization/society</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mandate holder</strong></td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. med. K. J. Neis1,3</td>
<td>German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe [DGGG])</td>
</tr>
<tr>
<td>Prof. Dr. med. K. Schwedtpleger4</td>
<td>AWMF Guideline consultant</td>
</tr>
<tr>
<td><strong>Other participating authors contributing to the guideline:</strong></td>
<td></td>
</tr>
<tr>
<td>Dr. med. W. Zubke2,3</td>
<td>German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe [DGGG])</td>
</tr>
<tr>
<td>Prof. Dr. med. K. Tamussino2,3</td>
<td>Austrian Society of Gynecology and Obstetrics (Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])</td>
</tr>
<tr>
<td>Prim. Dr. med. W. Stammwoll †</td>
<td>Austrian Society of Gynecology and Obstetrics (Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])</td>
</tr>
<tr>
<td>PD Dr. med. M. Fehr2</td>
<td>Swiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])</td>
</tr>
<tr>
<td>Prof. Dr. med. A. Kuhn3</td>
<td>Swiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])</td>
</tr>
<tr>
<td>Prof. Dr. med. M. Müller3</td>
<td>Swiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])</td>
</tr>
<tr>
<td>Prof. Dr. med. B. Bojahr</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>PD Dr. med. S. Rimbach</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Prof. Dr. med. T. Römer2,3</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Prof. Dr. med. E. Solomayer3</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Dr. med. T. Schollmeyer †</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Dr. med. B. Holthaus</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Dr. med. F. Neis3</td>
<td>Working Group for Gynecological Endoscopy (Arbeitsgemeinschaft Gynäkologische Endoskopie [AGE])</td>
</tr>
<tr>
<td>Prof. Dr. med. B. Gabriel</td>
<td>Working Group for Urogynecology and Reconstructive Pelvic Surgery (Arbeitsgemeinschaft für Urogynäkologie und plastische Beckenbodenrekonstruktion [AGUB])</td>
</tr>
<tr>
<td>Prof. Dr. med. C. Reisenauer3</td>
<td>Working Group for Urogynecology and Reconstructive Pelvic Surgery (Arbeitsgemeinschaft für Urogynäkologie und plastische Beckenbodenrekonstruktion [AGUB])</td>
</tr>
<tr>
<td>Dr. med. H. Dieterich</td>
<td>Working Group for Esthetic, Plastic and Reconstructive Surgery in Gynecology (Arbeitsgemeinschaft für ästhetische, plastische und wiederherstellende Operationsverfahren in der Gynäkologie [AWOGyn])</td>
</tr>
<tr>
<td>Prof. Dr. med. I. B. Runnenbaum3</td>
<td>Working Group Gynecologic Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie [AGO])</td>
</tr>
<tr>
<td>Prof. Dr. med. W. Kleine</td>
<td>Working Group Gynecologic Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie [AGO])</td>
</tr>
<tr>
<td>Prof. Dr. med. A. Strauss3</td>
<td>Working Group for Ultrason Diagnosis in Gynecology and Obstetrics (Arbeitsgemeinschaft für Ultraschalldiagnostik in Gynäkologie und Geburtshilfe [AGULS])</td>
</tr>
<tr>
<td>Prof. Dr. med. M. Menton3</td>
<td>Committee on Cervical Pathology and Colposcopy (Arbeitsgemeinschaft Zervixpathologie &amp; Kolposkopie [AGCPC])</td>
</tr>
<tr>
<td>Prof. Dr. med. I. Mylonas3</td>
<td>Working Group for Infectious Diseases and Infection Immunology (Arbeitsgemeinschaft Infektions- und Infektiologie [JAG])</td>
</tr>
<tr>
<td>Prof. Dr. M. David4</td>
<td>German Society for Psychosomatic Gynecology and Obstetrics (Deutsche Gesellschaft für Psychosomatische Frauenheilkunde und Geburtshilfe [DGGF])</td>
</tr>
<tr>
<td>Prof. Dr. med. L-C. Horn</td>
<td>German Society of Pathology (Deutsche Gesellschaft für Pathologie [DGP])</td>
</tr>
<tr>
<td>Federal Association of Pathologists (Berufsverband Deutsche Pathologen [BDP])</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. med. D. Schmidt</td>
<td>German Society of Pathology (Deutsche Gesellschaft für Pathologie [DGP])</td>
</tr>
<tr>
<td>Federal Association of Pathologists (Berufsverband Deutsche Pathologen [BDP])</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. med. A. T. Teichmann</td>
<td>Association of Head Physicians of Gynecological and Obstetric Hospitals (Bundesarbeitsgemeinschaft Leitender Ärzte in der Frauenheilkunde und Geburtshilfe [BLFG])</td>
</tr>
<tr>
<td>Dr. med. P. Brandner3</td>
<td>Federal Association of Gynecologists (Bundesarbeitsverband der Frauenärzte e. V. [BVF])</td>
</tr>
<tr>
<td>Dr. M. Nothacker4</td>
<td>AWMF Guideline consultant</td>
</tr>
</tbody>
</table>

1 methodological support, drafting of the guideline report, 2 member of the steering committee, 3 participant in the nominal group process entitled to vote, 4 drafting of the evidence report

---

**Schlussfolgerung:** Ziel der Aufklärung ist, die Patientin in die Lage zu versetzen, unter den Therapieoptionen für benign Uterusrerkrankungen diejenige herauszufinden, die am besten zu ihr und ihrer Lebenssituation passt.
Abbreviations

AGPC Committee on Cervical Pathology and Colposcopy
AGE Working Group for Gynecological Endoscopy
AGII Working Group for Infectious Diseases and Infection Immunology
AGO Working Group Gynecologic Oncology
AGUB Working Group for Urogynecology and Reconstructive Pelvic Surgery
AIS adenocarcinoma in situ
ARGUS Working Group for Ultrasound Diagnosis in Gynecology and Obstetrics
AWMF Association of the Scientific Medical Societies in Germany
BVF Federal Association of Gynecologists
BLFG Association of Head Physicians of Gynecological and Obstetric Hospitals
CIN cervical intraepithelial neoplasia
DGFG German Society for Psychosomatic Gynecology and Obstetrics
DGGG German Society of Gynecology and Obstetrics
DGP German Society of Pathology
ETC European Training Centre for Gynecologic Endoscopy
GnRH gonadotropin releasing hormone
GR Grade of recommendation
HE hysterectomy
HPV human papilloma virus
IUS intrauterine system
LASH laparoscopically assisted supracervical hysterectomy
LAVH laparoscopically assisted vaginal hysterectomy
LoE Level of evidence
OEGGG Austrian Society of Gynecology and Obstetrics
SGGG Swiss Society of Gynecology and Obstetrics
TLH total laparoscopic hysterectomy

II Using this Guideline

Purpose and objectives
This guideline concerns hysterectomy performed in patients with benign diseases. It aims to examine the entire range of surgical procedures as well as the associated context in order to permit optimal treatment of women in each case. The guideline presents and evaluates the individual indication areas, describes the hysterectomy routes, evaluates the advantages and disadvantages of individual surgical techniques and presents possible alternatives. The guideline aims to provide a basis that women can use to obtain in-depth information in order to make a decision about the treatment plan in consultation with their doctor based on their knowledge of the advantages and disadvantages of the specific procedure and of the effects of the operation on their quality of life. In these times of increasing cost pressure in the health care system, it is also essential to include this aspect in the considerations.

Targeted patients
Patients with an equivocal indication for hysterectomy and patients who have undergone a hysterectomy.

Target audience
The guideline addresses members of the health care profession involved in performing this surgical procedure. A medical background is required to understand this guideline.

This guideline is aimed at the following groups of people:
- gynecologists in private practice
- gynecologists working in a clinical setting
- nursing professionals
- the cooperating partners of the medical profession (e.g. health care professionals, payers)
- the patients concerned and their personal setting (partners, etc.)
- the general public, in order to provide it with information about sound medical approaches

Period of validity
The validity of this guideline was confirmed by the chairpersons/heads of the participating medical societies/organizations/associations and by the head of the DGGG and the DGGG Guideline Commission in April 2015, thereby also confirming the entire contents of the guideline. This guideline is valid until April 30, 2020. This period of validity was estimated based on the contents of the guideline. If need be, the guideline can be updated before it has expired; if the guideline is still considered to represent the current state of knowledge, its period of validity can be extended.

III Guideline

1 Methodology
1.1 Principles
The methodology for the compilation of this guideline is prescribed by the classification assigned to the guideline. The AWMF Guidance Manual and Rules for Guideline Development (Version 1.0) sets out the rules for classifying guidelines. Guidelines are differentiated into lowest (S1), moderate (S2) and highest (S3) class. The lowest class of guideline is defined as consisting of a set of recommendations for action compiled by a non-representative group of experts. In 2004 the S2 class was divided into two subclasses: S2e (evidence-based) and S2k (consensus-based). The highest class (S3) combines both approaches. This guideline is classified as S3.

1.2 Literature search
The following literature databases were searched:
- Cochrane Menstrual Disorders and Subfertility Group specialized register of controlled trials
- Central
- MEDLINE
- Embase
- Biological Abstracts
- The National Research Register
The following keywords were used for the search:
- hysterectomy CRT
- hysterectomy
- vaginal
- abdominal
- LAVH
- LASH
- TLH
- myoma
- endometriosis
- adenomyosis
- descensus
- incontinence
The classification of “Recommendations” presented above corresponds to both the evaluation of evidence and the clinical relevance of the studies on which they are based and their scope/factors not listed in the grading of the evidence, such as the selection of patient cohort, intention-to-treat or per-protocol outcome analyses, medical or ethical action toward the patient, country-specific applicability, etc. Conversely, a strong, moderate or weak level of evidence can lead to strong, regular or open recommendations in a related linear fashion. The only level that permits both an upward and downward classification is the moderate evidence level, in which a translation into level A or level 0 is possible. In special exceptional cases, converting the highest evidence level into the weakest/an open recommendation or vice versa must be explained in the background text.

▶ complications
▶ quality of life

The search encompassed the period from January 1990 to November 2011. In addition, MEDLINE was specifically searched with regard to certain questions. In order to achieve a transparent and up-to-date evidence base, an updated literature search was performed in MEDLINE (via PubMed) in 2013–2014 on the following topics:

▶ comparison of hysterectomy routes
▶ comparison of hysterectomy to uterine artery embolization or myomectomy for symptomatic uterine fibroids
▶ comparison of hysterectomy and drug therapy for uterine fibroids, dysfunctional menstrual disorders or adenomyosis.

The results of the literature search were included in the current version of the guideline.

1.3 Evidence tables

1.3.1 Evidence grading based on the Oxford Centre for Evidence-Based Medicine levels of evidence

To evaluate the evidence (levels 1 to 5), the Oxford Centre for Evidence-Based Medicine classification system was used in its most recent version published in 2009 as Level of Evidence (LoE).

1.4 Recommendation grading

Pure evidence grading of a guideline at S2e/S3 level based on the Oxford classification can be translated into a grade of recommendation (GR) for a guideline. This symbolic recommendation level is divided into three gradations with various degrees of linguistic expression (Table 2).

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description of binding nature</th>
<th>Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Strong recommendation with highly binding character</td>
<td>must (soll) / must not (soll nicht)</td>
</tr>
<tr>
<td>B</td>
<td>Regular recommendation with moderately binding character</td>
<td>should (solllte) / should not (solllte nicht)</td>
</tr>
<tr>
<td>0</td>
<td>Open recommendation with limited binding character</td>
<td>may (kann) / does not need to (kann nicht)</td>
</tr>
</tbody>
</table>

The numbers in Germany were as follows in 2012: uterine fibroids: 60.7%, prolapse: 27.9%, menstrual problems: 25.2%, hyperplasia and atypia of the endometrium: 2.9, and endometriosis: 15.1% of cases [1].

1.5 Statements

If statements by specialists are included in this guideline that are not intended as recommendations for action, but rather simply for the purpose of presentation, these are referred to as “statements”. For these statements, it is not possible to indicate evidence levels.

1.6 Consensus strength

As part of a structured consensus agreement process (S2k/S3 level), the eligible participants at the meeting agree on the statements and recommendations that were drawn up. During this process, significant modifications to the wording may occur. Subsequently, the consensus strength is determined based on the number of participants (Table 3).

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Consensus strength</th>
<th>Agreement in percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>+++</td>
<td>Strong consensus</td>
<td>Agreement of &gt; 95% of the participants</td>
</tr>
<tr>
<td>++</td>
<td>Consensus</td>
<td>Agreement of &gt; 75–95% of the participants</td>
</tr>
<tr>
<td>+</td>
<td>Majority agreement</td>
<td>Agreement of &gt; 50–75% of the participants</td>
</tr>
<tr>
<td>–</td>
<td>No consensus</td>
<td>Agreement of &lt; 50% of the participants</td>
</tr>
</tbody>
</table>

1.7 Expert consensus

As the name suggests, “expert consensus” refers to consensus decision specifically for recommendations/statements without a prior systematic literature search (S2k) or based on the missing evidence (S2e/S3). The term “expert consensus (EC)” to be used is synonymous with terms from other guidelines such as “good clinical practice (GCP)” or “clinical consensus point (CCP)”. The recommendation strength is graded similarly to the aforementioned classification without the use of the symbols and is expressed in purely semantic terms (“must”/“must not” or “should”/“should not” or “may”/“does not need to”).

2 Introduction

All of the sections below are excerpts from the long version of the guideline and do not claim to be complete. Only the sections of the long version are mentioned that contain consensus- and/or evidence-based statements or recommendations. Sections without these particulars are described briefly at most. To obtain more information (background texts, additional literature citations) on existing sections or sections not listed here, please download the long version (see Guideline documents).

3 Indications and contraindications

3.1 Indications

Common indications for performing hysterectomy for benign diseases include the following: uterine fibroids, menstrual disorders, adenomyosis of the uterus, endometriosis, uterine prolapse and precancerous lesions of the endometrium and the cervix. The numbers in Germany were as follows in 2012: uterine fibroids: 60.7%, prolapse: 27.9%, menstrual problems: 25.2%, hyperplasia and atypia of the endometrium or cervix: 2.9, and endometriosis: 15.1% of cases [1].
Due to the comorbidities, a total of nearly 130% is reached. This also reflects clinical reality, in which the histologically ascertainable findings of uterine fibroids, adenomyosis and endometriosis often coincide. The clinical picture of “menstrual problems” as an umbrella term encompasses hypermenorrhea, dysmenorrhea and dyspareunia. For this reason, it is often difficult to list and code a single diagnosis as the indication for hysterectomy. This overlapping also means that experts may disagree about the treatment plan to be used in a particular case. Thus, when indicating surgery for these conditions, personal experience, especially the mastery of a certain surgical technique or with the use of alternatives, plays a significantly greater role than for cancer, for example, for which treatment is based on a single hard diagnosis.

Due to this special situation, it is particularly important to inform the patient about the range of treatment options, about the recommended procedure, the associated risks and to clearly point out the advantages and disadvantages of each surgical technique that can be expected and if the merits of techniques “compete with” each other. Ultimately, the decision as to whether hysterectomy is indicated, as well as on using alternative methods, must be made by an informed patient along with her attending physician. For this reason, the term “informed consent and shared decision-making” has become established.

3.2 Hysterectomy for uterine fibroids
Consensus-based recommendation 3.1
For suspected symptomatic uterine fibroids, the first step is to clarify whether the symptoms are actually caused by uterine fibroids. (expert consensus)
Consensus strength (+++)

Consensus-based recommendation 3.2
If the symptoms are caused by fibroids, depending on the patient’s life circumstances, the treatment decision must be made together with the patient. (expert consensus)
Consensus strength (+++)

Consensus-based recommendation 3.3
Hysterectomy may be performed in the case of symptomatic uterine fibroids, if fertility is no longer desired, if treatment alternatives have failed and/or as requested by the patient. (expert consensus)
Consensus strength (+++)

Evidence-based statement 3.51
For preoperatively anemic patients with uterine fibroids, drug therapy with GnRH analogues or Ulipristal may be indicated prior to hysterectomy. (LoE_{Oxford} 2009 1a [GnRH analogues], 1b [Ulipristal])
Consensus strength (+++)
Literature: GnRH analogues [2, 3] and Ulipristal [4, 5]

3.3 Dysfunctional uterine bleeding
Consensus-based recommendation 3.4
For abnormal uterine bleeding, premalignant or malignant lesions must be excluded prior to further treatment. (expert consensus)
Consensus strength (+++)

Evidence-based statement 3.52
If hormone therapy has failed and fertility is no longer desired, endometrial ablation and hysterectomy is a treatment option. (LoE_{Oxford} 2009 1a)
Consensus strength (+++)
Literature: [6]

Consensus-based recommendation 3.5
If endometrial ablation has failed, a hysterectomy must be performed. (expert consensus)
Consensus strength (+++)

3.4 Endometriosis/adenomyosis
Evidence-based recommendation 3.6
To confirm the diagnosis of adenomyosis/endometriosis, a detailed history and an ultrasound examination should be performed. (LoE_{Oxford} 2009 1b, GR A)
Consensus strength (+++)
Literature: [7]

Consensus-based recommendation 3.7
For suspected endometriosis, laparoscopy should also be performed. (expert consensus)
Consensus strength (+++)

Consensus-based recommendation 3.8
If hormone therapy has failed and fertility is no longer desired, a hysterectomy should be performed. (expert consensus)
Consensus strength (+++)

Consensus-based statement 3.53
For deep infiltrating endometriosis, a hysterectomy may be indicated in the overall concept of complete resection. (expert consensus)
Consensus strength (+++)
Literature: Expert consensus based on S2k Guideline for the Diagnosis and Treatment of Endometriosis [8]

3.5 and 3.6 Cytological suspicion of endometrial and glandular precancers
Consensus-based recommendation 3.10
Microscopically confirmed CIN alone, regardless of severity, is not an indication for hysterectomy. In the case of persistent HPV detection after conization alone, hysterectomy must not be performed. If there is a cytological or microscopic diagnosis of an adenocarcinoma in situ (AIS) of the cervix, conization with endocervical curettage of the high cervical canal must be performed (not a primary hysterectomy) in order to rule out an invasive adenocarcinoma.
If there is a cytological or microscopic diagnosis of an adenocarcinoma in situ (AIS) of the cervix, a primary hysterectomy must not be performed in order to rule out an invasive adenocarcinoma. Instead, conization with endocervical curettage of the high cervical canal must be performed. Hysterectomy may be performed after conization in the case of residual recurrent CIN 2/3 or glandular neoplasia located in the low cervical canal. (expert consensus)

Consensus strength (+++)

Literature: These recommendations were adopted in the expert consensus based on the S2 Guidelines for HPV infection/pre-invasive lesions of the female genitals: Prevention, Diagnosis and Treatment [9].

3.7 Atypical endometrial hyperplasia in the histology of the aspiration or of the curettage material

Consensus-based recommendation 3.E11

For atypical endometrial hyperplasia in women no longer desiring fertility, hysterectomy must be performed. (expert consensus)

Consensus strength (+++)

3.8 Prolapse

Consensus-based statement 3.S4

The uterus may be retained during surgery for uterine prolapse. (expert consensus)

Consensus strength (+++)

Literature: Expert consensus based on the Guidelines for diagnosing and treating uterine prolapse [10]

Consensus-based recommendation 3.E12

If the uterus is retained, the presence of a malignant tumor should be excluded. (expert consensus)

Consensus strength (+++)

3.9 Urinary incontinence and hysterectomy

Evidence-based recommendation 3.E13

Hysterectomy for incontinence problems must be separately indicated. (LoEOxford 2009 2–3, GR A)

Consensus strength (+++)

Literature: [11]

3.10 Infections

Consensus-based statement 3.S5

To treat an infectious disease of the internal genitals, hysterectomy may be indicated in certain circumstances. (expert consensus)

Consensus strength (+++)

3.11 Chronic pelvic pain

Consensus-based recommendation 3.E14

Laparoscopy should be performed before performing a hysterectomy for chronic pelvic pain. (expert consensus)

Consensus strength (++)

Literature: Expert consensus based on the Guidelines for diagnosing chronic pelvic pain in women [12]

Evidence-based recommendation 3.E15

When indicating hysterectomy for chronic pelvic pain, the decision must be made in cooperation with the patient based on interdisciplinary findings and the patient must be informed about the high failure rate. (LoEOxford 2009 2a-, GR A)

Consensus strength (+++)

Literature: [13, 14]

3.12 Elective hysterectomy

Consensus-based recommendation 3.E16

A hysterectomy that is not medically indicated to be undertaken only at the patient’s request should not be performed. (expert consensus)

Consensus strength (+++)

3.13 Emergency hysterectomy (nonpuerperal)

Consensus-based statement 3.S6

In rare cases, a nonpuerperal emergency hysterectomy is indicated (trauma, coagulation disorder, bleeding, infection). (expert consensus)

Consensus strength (++)

4 Alternatives to hysterectomy

4.1 Uterine fibroids

When choosing an alternative to hysterectomy, the effectiveness and safety of the selected treatment method and the risk of fibroid recurrence should be weighed against the (potential) advantages of retaining the uterus (lower morbidity and retained fertility). In the end, rare complications may necessitate the actually unwanted hysterectomy [15].

Consensus-based recommendation 4.E17

Patients must be informed about the individual success and failure rates related to the various methods of fibroid treatment. (expert consensus)

Consensus strength (+++)

4.2 Menstrual disorders

A number of reasons are responsible for menstrual disorders. Around 50% of menstrual disorders have organic causes. These cases require causal treatment such as hysteroscopic polyp and fibroid resection (see also Uterine fibroids) or treatment of adenomyosis or endometrial hyperplasia. If organic causes have been ruled out, intermenstrual and dysfunctional bleeding can generally be treated with hormones, primarily progestogens, and in some cases, also estrogens. The primary indications for hysterectomy are refractory hypermenorrhea and menorrhagia. Before resorting to hysterectomy, the patient should receive in-depth information about the wide range of proven alternatives.

Evidence-based recommendation 4.E18

Patients must be informed about the individual success and failure rates related to the various methods of menstrual disorder treatment. (LoEOxford 2009 Tb [LNG-IUS], 1a [endometrial ablation], GR A)

Consensus strength (+++)

Literature: LNG-IUS [16, 17] and endometrial ablation [18]
5 Information and consent
Preoperative information and consent includes the following:
- the indication and objective of the procedure including an assessment of the probability of success
- presentation of options for treatment/methods, including nonsurgical alternatives
- explanation of the preferred method
- description of procedure-related risks and typical complications, including their sequela
- information about patient behavior before and after the procedure.

Consensus-based statement 5.57
The nature, scope, time and form of information and consent are based on the patient’s individual situation, the legal provisions and current case rulings. Treatment options, side effects and probability of success must be presented. (expert consensus) Consensus strength (+++)

6 Perioperative management
Hysterectomy is a procedure that generally involves the same steps regardless of the indication. For this reason, for quality-related (and forensic) reasons, every hospital is advised to develop standards for perioperative management based on the current evidence. Perioperative checklists are recommended to prevent errors and ensure patient safety [19–24].

6.1 Preoperative management
Consensus-based recommendation 5.6.19
For patients with known or suspected organic or systemic disorders, the relevant laboratory parameters (e.g. for patients with bleeding disorders) must be determined. (expert consensus) Consensus strength (+++)

6.2 Intraoperative management
Evidence-based recommendation 6.6.20
Prophylactic antibiotics must be administered prior to hysterectomy. (LOE Oxford 2009 1a, GR A) Consensus strength (+++)
Literature: [25]

6.3 Postoperative management
Evidence-based recommendation 6.6.21
Perioperatively, risk-adapted thromboembolic prophylaxis must be administered. (LOE Oxford 2009 1a, GR A) Consensus strength (+++)
Literature: [26]

7 Surgical techniques
7.1 Vaginal hysterectomy
In addition to the general indication for a hysterectomy, the use of a vaginal approach involves the following special aspects:
- To ensure that the approach is reliable, the uterus must be sufficiently mobile. In general, with the patient under anesthesia, it should be possible to pull the portio to at least the mid-vagina. The vagina must be sufficiently broad and elastic for the surgery to be performed safely. In case of doubt, it may be helpful to perform the pelvic examination under anesthesia by pulling on the portio using bullet forceps.
- In the case of suspected extraterine pathology prior to surgery, for instance, in the adnexa, a laparoscopically assisted or abdominal approach should be favored.
- A vaginal approach is therefore particularly suitable for benign uterine diseases such as uterine prolapse. For nulliparous women and postmenopausal patients with atrophied vaginas and patients with long, narrow vaginas (obese patients) and patients with massively enlarged uteruses, the vaginal approach has its limits.
- However, the size of the uterus can be overcome by using morcellation or hemisection. As a rule of thumb, again depending on the sufficient breadth of access and the mobility of the organ, vaginal hysterectomy can be performed for a uterine size of around a 12-week pregnancy or a uterine weight of around 250 to 300 g. This corresponds to an average diameter of the uterine body of around 8 to 10 cm [27]. On the other hand, much larger uteruses can also be delivered safely using a vaginal approach [28].
- If a patient has already had a Cesarean section or undergone other pelvic surgery, vaginal hysterectomy can be much more difficult and the risk of injuring the bladder is increased. In this case, the situation must be taken into consideration when indicating vaginal hysterectomy.
- In the case of suspected or confirmed uterine or ovarian malignancy, a purely vaginal procedure should not be the primary choice. Selected patients with microinvasive cervical cancer or endometrial cancer are exceptions [29].

7.2 Laparoscopically assisted vaginal hysterectomy (LAVH)
Laparoscopically assisted vaginal hysterectomy (LAVH) combines laparoscopic and vaginal surgical techniques. The use of laparoscopy intends to avoid abdominal hysterectomy and enable vaginal hysterectomy. The laparoscopic part of the procedure includes all of the steps that cannot be performed vaginally or that can only be performed with a great deal of difficulty or increased risk (adhesiolysis, excision of endometriotic nodules, adnexectomy, detachment of the adnexa from the uterus). During LAVH, dissection in the area of the broad ligament of the uterus and the parametria ends above the ureterine artery, which is detached from the vaginal side. The uterus is extracted through the vagina and if needed, hemostomy or morcellation is carried out.
No specific contraindications applying only to LAVH are known. If laparoscopy is contraindicated in general, a purely vaginal or abdominal approach must be considered.

7.3 Total laparoscopic hysterectomy (TLH)
With total laparoscopic hysterectomy (TLH), all steps of the procedure are performed laparoscopically. In contrast to LAVH, the dissection of the ureterine artery is performed laparoscopically, as is the paracervical dissection up to the vagina, the detachment of the uterus from the vagina and the closure of the vagina by means of laparoscopic suturing. There is no switch from an abdominal to a vaginal approach. Due to the dissection, in particular in the area of the cervix, TLH must be learned as a separate surgical procedure, even by surgeons with laparoscopic experience [30]. For this reason, systematic reviews [31] report about elevated rates of complications, especially in the area of the ureteral tract, as well as increased risk of bleeding and relatively long operation times and recommend that this surgical procedure should be considered as a secondary choice. However, at centers with extensive TLH experience these problems have largely been resolved [30, 32]. Therefore, if there is sufficient experience with the technique, its complication rate is similar to that of other lap-
LASH is a procedure with a low complication rate after intraabdominal morcellation is removed via the trocar. The uterus is detached supracervically and the uterovesical fold. The complications reported for TLH, such as urinary tract lesions or dissection-related bleeding, are therefore rare for LASH.

7.4 Laparoscopic supracervical hysterectomy (LASH)

LASH constitutes an alternative to abdominal, total vaginal and total laparoscopic hysterectomy. In 2010, supracervical hysterectomy was performed in 13.5% of cases in Germany, most of them using a laparoscopic approach [1]. In the United States, 2% of all hysterectomies are performed supracervically, while in Scandinavia, around 36% of all hysterectomies are performed as supracervical hysterectomies [38].

With LASH, the first steps are performed similar to the procedure for LAVH and TLH and involve exposure of the site and dissection of possible associated pathologies (adhesions, endometriosis, adnexal abnormalities). Laparoscopic dissection ends at the level of the uterovesical fold. The uterus is detached supracervically and after intraabdominal morcellation is removed via the trocar.

LASH is a procedure with a low complication rate [39–41]. Detaching the uterine body from the cervix at the level of the isthmus means that surgery in the area of the parametria and dissection of the bladder is required to only a limited extent, if at all. The length of hospital stay did not differ. The complications reported for TLH, such as urinary tract lesions or dissection-related bleeding, are therefore rare for LASH.

7.5 Abdominal hysterectomy

In addition to the general indication for a hysterectomy, the use of the abdominal approach involves the following special aspects:

- In addition to oncological indications, the size of the uterus and associated disorders such as endometriosis or extensive adhesions resulting from previous surgery are indications for abdominal hysterectomy.
- An abdominal approach is also indicated depending on the individual situation in patients with a long, narrow vagina, for nulliparous women and patients with comorbidities and in patients for whom a vaginal or laparoscopic approach does not appear to be possible or would be associated with an increased complication risk. In case of doubt, when deciding whether abdominal hysterectomy is indicated, it may be helpful to perform the pelvic examination under anesthesia by pulling on the portio using bullet forceps.

7.6 Robot-assisted hysterectomy

Robot-assisted surgical procedures are used to a limited extent for treating gynecological and obstetrics patients. They are often indicated in patients with cancer. Robot-assisted hysterectomy can be implemented and can be performed quickly by a surgeon with laparoscopic experience [42,43]. Since the expenses and the operating time are far greater than those for conventional laparoscopy, in view of the limited resources, the use of robot-assisted hysterectomy must be decided on a case-by-case basis [44–47]. Systematic overview articles on robot-assisted hysterectomy (Tapper et al. 2014 [48], Liu et al. 2012 [49], Liu et al. 2014 [50]) identified the same 2 RCTs (Paraiso et al. 2013 [51], Sarlos et al. 2010 [46] [LoE 1b]). The interpretation of both RCTs showed differences in operating times. No differences were observed with regard to complications (blood loss, “minor” or “major” complications or postoperative use of pain medication).

With regard to quality of life, Sarlos et al. – without blinding – observed improvements in some aspects of quality of life after 3 weeks and after 6 to 8 weeks, while Paraiso et al. did not observe any differences after 6 months. In both studies, the operating time for robot-assisted hysterectomy was significantly longer than for laparoscopic surgery, with Paraiso observing an average longer time of 70 minutes and Sarlos reporting 20 minutes longer. They contained no information on transfusions. No information on complications or follow-up was reported. The procedure must still be considered to be experimental.
8 Intraoperative and postoperative complications

Table 4 Incidence of intraoperative and postoperative complications.

<table>
<thead>
<tr>
<th>(FINHYST 2011 (complication))</th>
<th>n = 5279 (%)</th>
<th>AQUA 2012 (complication)</th>
<th>n = 103232 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intraoperative blood loss ≥ 1000 ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>5.7</td>
<td>Intraoperative blood loss ≥ 1000 ml</td>
<td>No comparable data</td>
</tr>
<tr>
<td>LH</td>
<td>3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bladder injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>0.9</td>
<td>Bladder injury</td>
<td>0.59</td>
</tr>
<tr>
<td>LH</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ureter injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>0.3</td>
<td>Ureter injury</td>
<td>0.09</td>
</tr>
<tr>
<td>LH</td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bowel injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>0.2</td>
<td>Bowel injury</td>
<td>0.23</td>
</tr>
<tr>
<td>LH</td>
<td>0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postoperative bleeding or hematoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>2.6</td>
<td>Postoperative bleeding or hematoma</td>
<td>0.94</td>
</tr>
<tr>
<td>LH</td>
<td>2.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ileus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>1.0</td>
<td>Ileus</td>
<td>0.09</td>
</tr>
<tr>
<td>LH</td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary retention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>0.5</td>
<td>Urinary retention</td>
<td>No comparable data</td>
</tr>
<tr>
<td>LH</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>2.2</td>
<td>Urinary tract infection</td>
<td>1.0</td>
</tr>
<tr>
<td>LH</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wound infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>2.4</td>
<td>Wound infection</td>
<td>No comparable data</td>
</tr>
<tr>
<td>LH</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Febrile events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH</td>
<td>2.5</td>
<td>Febrile events</td>
<td>0.28</td>
</tr>
<tr>
<td>LH</td>
<td>1.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH</td>
<td>0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic infection, hematoma or abscess</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>1.00</td>
<td>Pelvic infection, hematoma or abscess</td>
<td>No comparable data</td>
</tr>
<tr>
<td>54</td>
<td>5.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>5.40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FINHYST study: n = 5279 with 1255 abdominal, 1679 laparoscopic and 2345 vaginal hysterectomies in Finland in 2006 [53]; AQUA 2012: n = 103232 independent of approach and distinction between endoscopically performed hysterectomies, only exact mention of 16196 abdominal hysterectomies and 57398 vaginal hysterectomies.

Abbreviations: AH = abdominal hysterectomy, LH = laparoscopic hysterectomy, VH = vaginal hysterectomy

9 Documentation

Every patient chart created for a patient undergoing a hysterectomy must include the indication, the symptoms and the findings of the patient. These comprise the general and specific history, especially previous illnesses and operations, as well as the general and gynecological examination results including imaging results.

Checklists have proven helpful for perioperative documentation.

The surgical report lists the date, diagnosis and summary of the treatment plan, along with the names of the physicians involved.

The surgical report serves as a description of the surgical procedure and the findings observed during surgery. In the case of an uncomplicated hysterectomy, this description may be brief. A surgical report becomes particularly important, however, if complications occur. It is recommended to clearly describe in the primary report any special anatomic circumstances and other conditions giving rise to complications. At critical points, such as in the case of parametric bleeding, the surgeon should state that he or she checked the ureter by means of inspection, palpation or exposure and acted properly and carefully.

The postoperative course must also be documented. The scope and results of a physical examination should be listed in the form of notes accompanied by the time of day. The same procedure should be used for findings from other hospitals and institutes.

The discharge summary is also very important.

10 Comparison of methods

In recent years, numerous publications and two systematic reviews have compared methods. The recommendation of the National Institute for Health and Care Excellence (NICE) [54] was first drawn up in 2002 and was adapted in 2004 and 2006. Independent of this recommendation, a Cochrane Review was conducted and published in 2009 [31], LoE 1a. For the most part, the reviews examine the same studies. Nieboer et al. recently evaluated 34 studies with a total of 4495 women. The NICE publication also evaluated a control study with 37049 women and a control study with 10100 women.

The advantages of vaginal hysterectomy compared to abdominal hysterectomy involved the significantly shorter recovery time (mean difference [MD] 9.5 days), fewer febrile episodes and unspecified infections (OR 0.42) and shorter hospital stays (MD 1.1
days). When comparing vaginal hysterectomy with laparoscopic hysterectomy (LH), no significant differences were found in this respect. However, the operating time was longer for LH (MD 39.3 minutes) and severe bleeding occurred more frequently (OR 2.76). The Cochrane Review concluded that owing to the same or significantly more favorable results across the board, vaginal hysterectomy should be preferred over abdominal hysterectomy whenever possible. If a vaginal hysterectomy is not possible, laparoscopic procedures can be used to avoid the disadvantages of a laparotomy due to the more favorable adverse effect profile [27]. The American College of Obstetricians and Gynecologists came up with the same recommendations [55]. Diverse comparative analyses have come up with identical results for the procedure with the lowest costs, which is vaginal hysterectomy.

In addition to the systematic review by Nieboer et al., after updating the search to include publications up to June 2014, other systematic overview articles were included on the following issues related to the comparison of methods (Tables 5 and 6):

### Table 5: Comparison of hysterectomy methods

<table>
<thead>
<tr>
<th></th>
<th>Vaginal hysterectomy vs. abdominal hysterectomy</th>
<th>LH vs. abdominal hysterectomy</th>
<th>Vaginal hysterectomy vs. LH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating time</td>
<td>Quicker return to normal activity</td>
<td>Return to normal activity</td>
<td>Shorter operating time</td>
</tr>
<tr>
<td></td>
<td>Average difference 9.5 days</td>
<td>Average difference 13.6 days</td>
<td>Average 2.3 min</td>
</tr>
<tr>
<td>Blood loss</td>
<td>Fewer febrile events, fewer febrile episodes and specific infections</td>
<td>Lower blood loss</td>
<td>Lower drop in HB</td>
</tr>
<tr>
<td></td>
<td>OR 0.42; CI 0.21–0.83</td>
<td>Average 45 cm³</td>
<td>Average difference 0.55 g/dl</td>
</tr>
<tr>
<td>Complications</td>
<td>Shorter hospital stay</td>
<td>Shorter hospital stay</td>
<td>Longer operating time</td>
</tr>
<tr>
<td></td>
<td>Average difference 1.1 days</td>
<td>Average difference 2.0 days</td>
<td>Average 2.3 min</td>
</tr>
<tr>
<td>Admission period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Return to work</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 6: Comparison of different hysterectomy modalities.

<table>
<thead>
<tr>
<th></th>
<th>Operating time</th>
<th>Blood loss</th>
<th>Complications</th>
<th>Admission period</th>
<th>Return to work</th>
<th>Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal hysterectomy</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>LAVH</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>TLH</td>
<td>++</td>
<td>+(+*)</td>
<td>+(+)</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>LASH</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Abdominal HE</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Number of “*” means increasing advantage of the method.

**Evidence-based recommendation 10.E22**
If possible, vaginal hysterectomy must be favored over abdominal hysterectomy. ([LoE Oxford 2009 1a, GR A])

**Consensus strength (+++)**

Literature: [42, 56, 57]

**Evidence-based recommendation 10.E23**
If vaginal hysterectomy is not possible, the possibility of laparoscopic hysterectomy should be reviewed. ([LoE Oxford 2009 1a, GR B])

**Consensus strength (+++)**

Literature: [42, 58]

**Evidence-based recommendation 10.E24**
LASH may be performed as an alternative to abdominal hysterectomy and vaginal hysterectomy. ([LoE Oxford 2009 1a, GR 0])

**Consensus strength (+++)**

Literature: [59]

**Consensus-based statement 10.S8**
However, current data do not permit the different laparoscopic techniques to be exactly differentiated. ([expert consensus])

**Consensus strength (+++)**

**Consensus-based recommendation 10.E25**
Abdominal hysterectomy should only be performed if it is specifically indicated. ([expert consensus])

**Consensus strength (+++)**

**Evidence-based statement 10.S9**
In the available randomized studies, no confirmed patient-related benefits were found for the use of robot-assisted technology. ([LoE Oxford 2009 1b])

Literature: [45–47]

### 11 Special situation – What do I do if...?

#### 11.1 Hysterectomy for adenomyosis/endometriosis

**Consensus-based recommendation 11.E26**
If the patient has the relevant symptoms, there is no desire for fertility and there are clinical signs of adenomyosis, a hysterectomy should be performed. ([expert consensus])

**Consensus strength (+++)**

**Consensus-based statement 11.S10**
For deep infiltrating endometriosis, a hysterectomy may be indicated in the overall concept of complete resection. ([expert consensus])

**Consensus strength (+++)**
11.2 Hysterectomy and incontinence
If a patient for whom a hysterectomy is indicated is to undergo surgery for stress incontinence at the same time, the hysterectomy may be performed using the most straightforward procedure. The stress incontinence surgery does not impact the method used for hysterectomy.

11.3 Obstetric hysterectomy for postpartum hemorrhage
Consensus-based recommendation 11.E27
For postpartum, life-threatening uterine bleeding and the failure of alternative treatment options, a hysterectomy is indicated as a last resort and in the event of a life-threatening situation. (expert consensus)
Consensus strength (+++)

12 Quality of life
Evidence-based recommendation 12.E28
Patients should be informed that after they have undergone an indicated hysterectomy, they can generally expect to experience improvement in quality of life and sexual functioning compared to their preoperative situation. (LoE Oxford 2009 1a, GR B)
Literature: [60–63]

Evidence-based statement 12.S11
A prophylactic bilateral adnexectomy may be associated with undesired long-term adverse effects and requires separate information and consent. (LoE Oxford 2009 1a)
Consensus strength (++)
Literature: [64, 65]

13 Algorithm: Alternatives to hysterectomy
(● Figs. 1 to 3)

![Algorithm: Alternatives to hysterectomy](image)

**Fig. 1** Pathway: Uterine fibroids.
**Fig. 2** Pathway: Menstrual disorder.

1. **Menstrual disorder**
   - Oral contraceptives possibly long-term use
     - Symptoms improved? Yes
     - Progestogens
       - systemic
       - local
     - Symptoms improved? Yes
     - Fertility no longer desired? No
     - Plan a pregnancy
     - Discontinue treatment
   - No

**Fig. 3** Pathway: Endometriosis/adenomyosis.

1. **Endometriosis/adenomyosis**
   - Oral contraceptives
     - Preferably long-term use
     - Symptoms improved? Yes
     - Progestogens
       - systemic
       - local
     - Symptoms improved? Yes
     - Fertility no longer desired? No
     - Patient would like...
   - Short-term use of GnRH analogues (monitor for adverse effects!)
     - Symptoms improved? Yes
     - Discontinue treatment
     - No
   - Plan a pregnancy
   - Hysterectomy
     - Symptoms improved? No
     - Fertility no longer desired? Yes
     - No
Affiliations
1 Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin der Universitätsklinik des Saarlandes
2 Frauenklinik des Universitätsklinikums Tübingen
3 Evangelisches Krankenhaus Köln-Weyertal
4 Klinik für Neurochirurgie der Universitätsklinik des Saarlandes
5 Klinik für Gynäkologie und Geburtshilfe Universitätsklinikum Schleswig-Holstein
6 Klinik für Gynäkologie und Geburtshilfe Krankenhaus Agatharied GmbH
7 Klinik für Frauenheilkunde und Geburtshilfe St. Elisabeth Krankenhaus Damme
8 Klinik für MIC Minimal Invasive Chirurgie am Ev. Krankenhaus Hubertus
9 Klinik für Gynäkologie und Geburtshilfe Krankenhaus der Barmherzigen Schwestern Linz
10 Frauenärzte-West Saarbrücken
11 Universitätsklinikum Erlangen Frauenklinik
12 Institut für Pathologie Mannheim
13 Universitätsklinikum Mannheim Klinik für Frauenheilkunde und Geburtshilfe
14 Klinik für Gynäkologie und Geburtshilfe Christian-Albrechts-Universität zu Kiel
15 Dysplasiezentrum Reutlingen
16 Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Klinikum der Universität München
17 Campus Virchow-Klinikum Charité Klinik für Gynäkologie
18 Institut für Pathologie Universitätsklinikum Leipzig
19 Institut für Pathologie Mannheim
20 Universitätsklinikum Erlangen Frauenklinik
21 Frauenklinik Aschaffenburg
22 Frauenärzte-West Saarbrücken
23 Krankenhaus der Barmherzigen Schwestern Lz
24 Inselspital Bern
25 Kantonsspital Frauenfeld
26 Universitäts-Frauenklinik Graz

References
16 Holhaus R. Komplikationen bei der TLH – ein 5-Jahres-Rückblick bei 800 Hysterektomien. ETC Saarbrücken, 2011; Vortrag Hysterektomie Workshop
54 NICE NIHRACE. Intervventional procedure overview of laparoscopic techniques for hysterectomy. Online: www.nice.org.uk/nicemedia/live/11045/38409/38409.pdf; last access: 11.01.2016
57 Garry R, Fountain J, Mason S et al. The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. BMJ 2004; 328: 129
Guideline Program

Editors
Leading Professional Medical Associations

German Society of Gynecology and Obstetrics
(Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. [DGGG])
Head Office of DGGG and Professional Societies
Hausvogteiplatz 12
DE-10117 Berlin
info@dggg.de
http://www.dggg.de/

President of DGGG
Prof. Dr. med. Diethelm Wallwiener
Universitätsfrauenklinik Tübingen
Calwerstraße 7
DE-72076 Tübingen

DGGG Guidelines Representative
Prof. Dr. med. Matthias W. Beckmann
Universitätsklinikum Erlangen
Frauenklinik
Universitätsstraße 21–23
DE-91054 Erlangen

Guidelines Coordination
Dr. med. Paul Gaß, Tobias Brodkorb, Marion Gebhardt
Universitätsklinikum Erlangen
Frauenklinik
Universitätsstraße 21–23
DE-91054 Erlangen
fk-dggg-leitlinien@uk-erlangen.de
http://www.dggg.de/leitlinienstellungnahmen

Austrian Society of Gynecology and Obstetrics
(Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])
Innrain 66A
AT-6020 Innsbruck
stephanie.leutgeb@oeggg.at
http://www.oeggg.at

President of OEGGG
Prof. Dr. med. Uwe Lang
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz
Auenbruggerplatz 14
AT-8036 Graz

OEGGG Guidelines Representative
Prof. Dr. med. Karl Tamussino
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz
Auenbruggerplatz 14
AT-8036 Graz

gynécologie suisse

Swiss Society of Gynecology and Obstetrics
(Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])
Gynécologie Suisse SGGG
Altenbergstraße 29
Postfach 6
CH-3000 Bern 8
sekretariat@sggg.ch
http://www.sggg.ch/

President of SGGG
Dr. med. David Ehm
FMH für Geburtshilfe und Gynäkologie
Nägeligasse 13
CH-3011 Bern

SGGG Guidelines Representative
Prof. Dr. med. Daniel Surbek
Universitätsklinik für Frauenheilkunde Geburtshilfe und feto-maternale Medizin
Inselspital Bern
Effingerstraße 102
CH-3010 Bern